OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 9
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 9
Showing 9 citing articles:
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 216-232
Closed Access | Times Cited: 11
Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 216-232
Closed Access | Times Cited: 11
TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
Florian P. Reiter, Andreas Geier
The Lancet (2025)
Closed Access | Times Cited: 1
Florian P. Reiter, Andreas Geier
The Lancet (2025)
Closed Access | Times Cited: 1
Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database
Shenkangle Wang, G. ren, Heng Pan, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Shenkangle Wang, G. ren, Heng Pan, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Early promising results with addition of an ICI and an anti-angiogenic to TACE
Diana Romero
Nature Reviews Clinical Oncology (2025)
Closed Access
Diana Romero
Nature Reviews Clinical Oncology (2025)
Closed Access
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access
Arndt Vogel, S.L. Chan, Laura A. Dawson, et al.
Annals of Oncology (2025)
Closed Access
Precision surgery for hepatocellular carcinoma
Christian Tibor Josef Magyar, Luckshi Rajendran, Zhihao Li, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access
Christian Tibor Josef Magyar, Luckshi Rajendran, Zhihao Li, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access
Combination locoregional and systemic therapies in hepatocellular carcinoma
Bin‐Yan Zhong, Wenzhe Fan, Justin J. Guan, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access
Bin‐Yan Zhong, Wenzhe Fan, Justin J. Guan, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
Hongyu Pan, Minghao Ruan, Riming Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Hongyu Pan, Minghao Ruan, Riming Jin, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
A new standard for HCC: The high stakes of TACE-immunotherapy combinations
María Teresa Salcedo, Lorenza Rimassa
Med (2025) Vol. 6, Iss. 3, pp. 100635-100635
Closed Access
María Teresa Salcedo, Lorenza Rimassa
Med (2025) Vol. 6, Iss. 3, pp. 100635-100635
Closed Access
Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study
Yasuhiro Fujisawa, Shusuke Yoshikawa, Tatsuya Takenouchi, et al.
International Journal of Clinical Oncology (2025)
Closed Access
Yasuhiro Fujisawa, Shusuke Yoshikawa, Tatsuya Takenouchi, et al.
International Journal of Clinical Oncology (2025)
Closed Access
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria
Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, et al.
Hepatology Research (2025)
Closed Access
Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, et al.
Hepatology Research (2025)
Closed Access
Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Qibin Wu, Xia Zhao, Chong Yang, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104730-104730
Closed Access
Qibin Wu, Xia Zhao, Chong Yang, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104730-104730
Closed Access
